Akoya BioSciences
AKYA
AKYA was delisted on the 7th of July, 2025.
68 hedge funds and large institutions have $69.7M invested in Akoya BioSciences in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 23 reducing their positions, and 9 closing their positions.
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
5% more funds holding
Funds holding: 65 → 68 (+3)
0.16% more ownership
Funds ownership: 30.07% → 30.23% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $80.1M → $69.7M (-$10.4M)
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Silvercrest Asset Management
New York
|
+$3.02M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.26M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.14M |
| 4 |
State Street
Boston,
Massachusetts
|
+$367K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$3.03M |
| 2 |
KLC
Kent Lake Capital
Reno,
Nevada
|
-$570K |
| 3 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$564K |
| 4 |
Millennium Management
New York
|
-$555K |
| 5 |
PCA
Peddock Capital Advisors
Braintree,
Massachusetts
|
-$263K |
AKYA Hedge Fund Activity: Q1 2024 in Review
68 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q1 2024, worth a combined $69.7M — down 13% from $80.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AKYA positions and 9 closed out — a net gain of 3 holders — while 17 added to existing stakes and 23 trimmed.
The largest buyer was Silvercrest Asset Management, opening a new position worth an estimated $3.02M. The largest seller was Board of Trustees of The Leland Stanford Junior University, exiting entirely with an estimated $3.03M sold.
- 68 institutional investors held Akoya BioSciences (AKYA) as of Q1 2024, up from 65 in Q4 2023.
- Funds reported $69.7M of Akoya BioSciences stock for Q1 2024, down 13% quarter-over-quarter.
- 12 funds opened new Akoya BioSciences positions in Q1 2024 and 9 closed out, a net change of +3 holders.
- The largest Akoya BioSciences buyer in Q1 2024 was Silvercrest Asset Management, an estimated $3.02M added.
- The largest Akoya BioSciences seller in Q1 2024 was Board of Trustees of The Leland Stanford Junior University, an estimated $3.03M sold.
Based on aggregated 13F filings for Q1 2024.